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ABSTRACT
The frequency of patients who switch to a second-line therapy from a frontline sec-
ond-generation (2gen) tyrosine kinase inhibitor (TKI) such as dasatinib and nilo-
tinib, is still substantially unknown. We retrospectively investigated a large series 
of chronic phase chronic myeloid leukemia (CP-CML) patients initially treated 
with 2gen TKIs monitored through the Italian Medicines Agency (AIFA Agenzia 
Italiana del farmaco) registries. Overall, 2420 patients were analyzed over a period 
of 6 years. One hundred and fifty-seven patients (16.3%) treated with dasatinib and 
164 treated with nilotinib (11.3%) have switched to another drug, with an overall 
frequency of 13.2%. In the dasatinib cohort, 39.4% of patients changed treatment 
for failure and 36.3% for intolerance as compared to 45.7% and 27.4% respectively 
in the nilotinib cohort. Overall, the median time to switch due to resistance was 
293 days, whereas it was 317 days in case of intolerance. Resistance was observed 
mainly in younger male patients with high-risk features, while intolerance was not 
related to any baseline parameter. After resistance/intolerance to nilotinib, the major-
ity of patients switched to dasatinib (53.8%) whereas in case of frontline dasatinib to 
ponatinib (43.2%). To the best of our knowledge these data provide the first report on 
the frequency of discontinuation of frontline 2gen TKIs and on the main causes and 
pattern of choice to a second-line therapy in the real-life setting.
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1 |  INTRODUCTION
The treatment of chronic myeloid leukemia (CML) has 
drastically changed since the introduction of imatinib, the 
first-generation tyrosine kinase inhibitor (TKI). Imatinib 
induced more than 85% of complete cytogenetic response 
(CCyR) with a major molecular response (BCR-ABL1 
ratio < 0.1% according to International Scale or 3 log-re-
duction) in approximately 60% of patients.1,2 However, 
despite these excellent results, more than 30% of treated 
subjects experienced treatment failure either for resistance 
or intolerance and had to be switched to a second-line 
therapy.3 Frontline treatment with second-generation 
TKIs (2gen TKIs), namely dasatinib and nilotinib, has 
further improved the outcome: although no differences in 
terms of overall survival have been detected as compared 
to imatinib, both these drugs induced faster and deeper 
molecular responses, decreasing the number of patients 
experiencing a progression to advanced phases of the dis-
ease.4,5 Despite the confirmed long-term results, some pa-
tients still experienced either failure or severe intolerance 
to 2gen TKIs requiring therefore a subsequent therapy. 
According to the only published experience on the out-
come of patients resistant/intolerant to a frontline 2gen 
TKI reported by MD Anderson Cancer Center (MDACC) 
out of 218 patients treated with dasatinib or nilotinib after 
a median follow-up of 23 months, 40 patients (18%) dis-
continued therapy, 25 initially treated with nilotinib (21% 
of all treated with nilotinib) and 15 (15%) initially treated 
with dasatinib. The majority of patients switched to a sub-
sequent line for intolerance (16 subjects) and only a minor 
percentage for resistance (5 patients) or for progression (4 
patients). Eleven subjects received imatinib as second-line 
therapy and only two patients switched to third-generation 
ponatinib.6 Considering the still persisting paucity of data 
on frequency and causes of discontinuation from frontline 
2gen TKIs and on second-line therapy selection, the aim 
of this study is to provide a real-life picture on these cru-
cial issues based on a large series of Italian patients from 
AIFA registries.
2 |  PATIENTS AND METHODS
For this analysis, we collected data from AIFA registries of 
all newly diagnosed chronic phase CML adult Italian patients 
treated with frontline dasatinib or nilotinib from January 
2013 to December 2018. The web-system allowed the stor-
ing and monitoring of clinical characteristics of patients 
eligible for treatment with 2gen TKIs according to prespeci-
fied criteria. Registered parameters for all TKIs were thera-
peutic drug indication, baseline characteristics (including 
age and Sokal score), patient outcome, treatment duration, 
principal reason for treatment discontinuation, occurrence 
of adverse reactions. According to Italian laws monitoring 
of these parameters does not require any informed consent 
or formal approval from ethical committees. Any included 
patient did receive, however, information about the purposes 
of the monitoring. Dasatinib and nilotinib eligibility form in-
cluded demographic data (place of birth, age, and sex) and 
the Sokal risk class.7 Prescription forms recorded the date 
of prescription, dose administered, and whether adverse re-
actions had occurred since the last prescription. Finally, the 
end of treatment form collected the reasons for treatment dis-
continuation. Time to treatment discontinuation (TTD) was 
defined as the time occurring between the initial prescrip-
tion and the date of treatment discontinuation for any cause, 
including death and lost to follow-up. A patient was defined 
“lost to follow-up” in the absence of any prescription or re-
evaluation for at least 180 days after the last registry entry. 
Switches to a different TKI were assessed considering also 
bosutinib and ponatinib as destination treatment, by checking 
the relative AIFA monitoring registries on the basis of a pa-
tient unique identifier. Since imatinib was not actively moni-
tored by AIFA, some uncertainties on subsequent switch to 
first-generation TKI remains for the patients that have been 
lost to follow-up. The time interval between the end of the 
first TKI treatment and the beginning of the second line was 
also evaluated, in order to rule out the possibility that other 
unmonitored therapy might have been administered between 
two subsequent recorded treatments.
3 |  RESULTS
From January 2013 to December 2018, 2.420 patients with 
newly diagnosed CP-CML treated with frontline 2gen TKIs 
were recorded into the AIFA registries. Of them, 964 pa-
tients (39.8%) were treated with dasatinib and 1456 (60.2%) 
with nilotinib. A change of therapy was recorded in 321 sub-
jects (13.2%), 157 (16.3%) of the dasatinib cohort, and 164 
(11.3%) of the nilotinib cohort. The median time for switch 
was 354 days, with a median of 386 days for dasatinib and 
323  days for nilotinib-treated patients. Overall, 6.9% of 
patients switched within 365  days from start of treatment, 
7.6% of the dasatinib cohort and 6.5% of the nilotinib co-
hort. Baseline features of CML patients treated with 2gen 
TKIs who change therapy are reported in Table 1. Overall, 
at the time of first prescription the median age was 54 years 
(range 21-83) with a prevalence of male patients (59.8%). 
The majority of patients were aged less than 65 years (76%) 
with only 77 older subjects (> or equal to 65 years, 23.9%). 
According to Sokal risk, 103 (32%) patients were classified 
as low risk, 118 (36.7%) as intermediate and 100 (31.1%) 
as high risk (Table 1). A comparison between the dasatinib 
and nilotinib populations revealed a significant difference 
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in terms of Sokal risk (P  <  .00001) and age at presenta-
tion, with patients treated with nilotinib being significantly 
younger than patients who received dasatinib (P < .00001). 
As far as the main reasons for discontinuation are concerned, 
137 subjects (42.68%) were considered as treatment failure, 
102 (31.78%) as intolerant, whereas 51 patients (15.89%) 
switched for nondrug-related reasons and in 31 patients 
(9.6%) the cause is missing.
Considering the 137 patients who changed therapy for 
resistance/progression (Table 2), the overall median time to 
the switch was 293 days, 286 days for dasatinib and 293 days 
for nilotinib-treated patients. Fifty-nine percent of patients 
switched within 365 days from treatment start. This cohort 
was represented mainly by male patients (63.5%), median age 
52 years, being only 25 of them (18.2%) aged ≥ 65 years. The 
majority of patients were classified as having at presentation 
a high Sokal risk (40.8%) or intermediate risk (33.5%) with 
only 25.5% being classified as low risk (Table 2).
One hundred and two patients switched for intolerance 
after a median time of 317 days, 386 for dasatinib and 189 for 
nilotinib-treated subjects (Table 3). We can speculate about 
the short time observed in nilotinib-treated patients implying 
T A B L E  1  Baseline features of whole cohort
Dasatinib Nilotinib Overall
(N = 157) (N = 164) (N = 321)
Gender—no. (%)
Female 63 (40.13%) 66 (40.24%) 129 
(40.19%)
Male 94 (59.87%) 98 (59.76%) 192 
(59.81%)
Age
Median—y 57 51 54
Range—y 21-82 21-83 21-83
<65 y 108 (68.79%) 136 (82.93%) 244 
(76.01%)
≥65 y 49 (31.21%) 28 (17.07%) 77 (23.99%)
Sokal score
Low-risk 41 (26.11%) 62 (37.80%) 103 
(32.09%)
Intermediate-
risk
63 (40.13%) 55 (33.54%) 118 
(36.76%)
High-risk 53 (33.76%) 47 (28.66%) 100 
(31.15%)
Switch 157 (16.3%) 164 (11.3%) 321 
(13.27%)
Switch per 
1000 y of 
treatment
69.6 45.7 55.0
Mean (median) 
days at switch
467 (386) 393 (323) 430 (354)
Switch within 
365 d from 
treatment start
73 (7.6%) 94 (6.5%) 167 (6.9%)
T A B L E  2  Resistant cohort: baseline features
Dasatinib Nilotinib Overall
(N = 62) (N = 75) (N = 137)
Gender—no. (%)
Female 21 (33.87%) 29 (38.67%) 50 (36.50%)
Male 41 (66.13%) 46 (61.33%) 87 (63.50%)
Age
Median—y 57 51 52
Range—y 24-82 21-83 21-83
<65 y 46 (74.19%) 66 (88.00%) 112 (81.75%)
≥65 y 16 (25.81%) 9 (12.00%) 25 (18.25%)
Sokal score
Low-risk 12 (19.35%) 23 (30.67%) 35 (25.55%)
Intermediate 23 (37.10%) 23 (30.67%) 46 (33.58%)
High-risk 27 (43.55%) 29 (38.67%) 56 (40.88%)
Mean (Median) 
days at switch
386 (286.5) 335 (293) 358 (293)
Switch within 
365 d from 
treatment start
34 (54.8%) 47 (62.7%) 81 (59.1%)
T A B L E  3  Intolerant cohort: baseline features
Dasatinib Nilotinib Overall
(N = 57) (N = 45) (N = 102)
Gender—no. (%)
Female 25 (43.86%) 24 (53.33%) 49 (48.04%)
Male 32 (56.14%) 21 (46.67%) 53 (51.96%)
Age
Median—r 60 51 57
Range—y 32-80 22-78 22-80
<65 y 32 (56.14%) 34 (75.56%) 66 (64.71%)
≥65 y 25 (43.86%) 11 (24.44%) 36 (35.29%)
Sokal score
Low-risk 15 (26.32%) 15 (33.33%) 30 (29.41%)
Intermediate-
risk
28 (49.12%) 18 (40.00%) 46 (45.10%)
High-risk 14 (24.56%) 12 (26.67%) 26 (25.49%)
MEAN (median) 
days at switch
517 (386) 327 (189) 434 (317)
Switch within 
365 d from 
treatment start
26 (45.6%) 32 (71.1%) 58 (56.9%)
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the possible related metabolic side effects which have required 
discontinuation. In this cohort there was a slight difference in 
terms of gender with 51.9% male and 48.1% of female sub-
jects. The median age was 57 years (range 22-80) with 35% 
of patients aged ≥ 65 years; no difference among Sokal risk 
classification at baseline was detected, being 29.4% low risk, 
45% intermediate and 25.4% as high risk (Table 3).
Details on second-line therapies after discontinuation of 
frontline dasatinib or nilotinib are reported in Figure 1. The 
majority of patients who changed from nilotinib, received as 
second-line dasatinib (53.8%), ponatinib (31.8%), or in lower 
percentage bosutinib (14.5%) while from dasatinib the ma-
jority of subjects switched to ponatinib (43.2%), 34% to nilo-
tinib and 22.8% to bosutinib. The choice of second line over 
time is represented in Figure 2.
4 |  DISCUSSION
Second-generation TKIs used as frontline treatment in-
creased the rate of faster and deeper molecular responses 
over time, reducing the possibility to experience a progres-
sion to advanced phase.8,9 As with imatinib, some patients 
can experience resistance and/or intolerance to these drugs, 
but remains still largely unknown how many patients treated 
outside clinical trials discontinue the treatment permanently. 
Until now only a few publications reported the outcome of 
frontline 2gen TKI CML-treated patients, in particular the 
SIMPLICITY trial10,11 and the MDACC experience.6 The 
SIMPLICITY trial is an observational study performed in 
US and six European countries with the primary aim of 
investigating the frontline TKI use and management pat-
terns in routine clinical practice. Twelve-month follow-up 
data are reported from October 2010 to September 2015; 
out of 1242 patients enrolled, 418 received dasatinib and 
408 were treated with nilotinib.10 Treatment selection was 
based on the baseline comorbidity profile with a predomi-
nance for 2gen TKIs from 2014 onward. A comparison 
of Italian rate of discontinuation with the other European 
countries showed a rate of permanent discontinuation in 
Italy in the first 12 months of 8.9% for dasatinib cohort and 
15.1% in the nilotinib-treated cohort, whereas in the rest of 
European countries it was of 19.6% for dasatinib and 13.8% 
for nilotinib.11
While the median time of discontinuation in Italy was 
4.6 and 5.5 months for dasatinib and nilotinib, respectively, 
in the remaining countries it was shorter being 4.4 months 
for dasatinib and 1.4  months for nilotinib. Intolerance was 
reported as the most frequent cause of first-line TKI dis-
continuation while primary resistance was the second most 
common one. No statistically significant predictive factors 
have been identified in the Italian population, whereas in 
the rest of European countries female and patients treated 
with imatinib were more likely to discontinue the treatment. 
While the switch to a second line occurred mostly between 3 
and 9 months for dasatinib-treated patients similarly to what 
F I G U R E  1  Second choice after 
discontinuation of first-line dasatinib (in 
red) or nilotinib (in green) for any reasons 
(panel A), for treatment failure (panel B) or 
intolerance (panel C). Second TKI bosutinib 
and ponatinib are blue and violet colored, 
respectively
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occurred for nilotinib, with imatinib the majority of patients 
switched earlier after 3 months of treatment.
As compared to this sponsored trial not representative of 
the actual real-life setting due to the criteria for selection of 
patients, according to our data from AIFA registries in Italy 
157 patients (16.3%) treated with frontline dasatinib and 164 
treated with nilotinib (11.3%) have switched to another drug, 
with an overall incidence of 13.2%. Differently from what 
usually reported in clinical trials, the main reason to discon-
tinue a frontline 2gen TKI seems to be resistance being 39.4% 
in the dasatinib-treated cohort compared to 45.7% in nilo-
tinib-treated patients. Interestingly, the majority of patients 
were aged less than 65  years (76%) with only 77 (23.9%) 
older subjects; it can be speculated that 2gen TKIs were used 
prevalently in younger patients, probably due to specific 
safety profile and that probably the rate of discontinuation is 
significantly lower, if compared to sponsored trials, due to the 
absence of dose modification and discontinuation forced cri-
teria. Overall, the Sokal risk stratification showed that the ma-
jority of patients who experienced resistance and failure were 
classified as having at presentation a high Sokal risk (40.8%) 
or intermediate risk (33.5%) with only 25.5% being classified 
as having a low Sokal risk. This is in line with the results of 
sponsored clinical trials showing an increased rate of events 
in high-risk patients as compared to low Sokal risk, both in 
terms of resistance and rate of progression; no difference was 
observed in Sokal risk stratification in the intolerant cohort 
analyzed. Median time to discontinuation was 9.5 months for 
dasatinib and 9.7 months for nilotinib: these data, indeed, in-
dicate a conservative approach of physicians when starting 
a frontline 2gen TKIs as compared to imatinib.12,13 In fact, 
with this latter drug a possible switch occurs more frequently 
after only 3 months. A real-life experience of outcome after 
discontinuation of 2gen TKIs was reported by MDACC group 
6: out of 218 patients frontline treated with dasatinib and ni-
lotinib 40 subjects (18%) discontinued the therapy, contrary 
to our experience, mostly for toxicity and only five patients 
for resistance; as in our study, the median time of discontinu-
ation was 8 months. Overall, as per second choice of TKIs it 
seems that ponatinib is preferred after resistance, in particular 
after dasatinib failure (66% of patients switched from dasat-
inib to ponatinib) probably due to high potency and multi-
target activity of the drug. Even after intolerance, ponatinib 
was chosen in 26% of patients after dasatinib and 13% after 
nilotinib, probably because it is possible to prescribe low dose 
of the drug. Since imatinib was not actively monitored by 
AIFA, some uncertainties on subsequent switch to first-gen-
eration TKI remains for the patients that have been lost to 
follow-up. Anyway, given the low percentage of these patients 
F I G U R E  2  Choice of second drug reported year by year in a period of 5 y
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(about 4% of the overall population), the number of putative 
switches to imatinib might be considered to be very low.
Despite some limitations due to the retrospective nature of 
this investigation and the lack of some clinical data not required 
by the AIFA registries as for instance on the outcome of patients 
experiencing a switch of therapy, our study representative of the 
Italian real-life setting showed that treatment discontinuation 
with frontline 2gen TKIs was relatively uncommon.
Further analyses are planned in order to acquire extensive 
data on patients treated with subsequent lines of therapy and 
subjects who attempt a discontinuation.
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